FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283711296> ?p ?o ?g. }

• W4283711296 endingPage "2165" @default.
• W4283711296 startingPage "2155" @default.
• W4283711296 abstract "Abstract Purpose Panitumumab plus FOLFOX (P-FOLFOX) is standard first-line treatment for RAS wild-type (WT) metastatic colorectal cancer. The value of panitumumab rechallenge is currently unknown. We assessed addition of panitumumab to FOLFIRI (P-FOLFIRI) beyond progression to P-FOLFOX in patients with no RAS mutations in liquid biopsy (LB). Methods In this randomized phase II trial, patients were assigned (3:2 ratio) to second-line P-FOLFIRI (arm A) or FOLFIRI alone (arm B). LB for circulating tumor DNA analysis was collected at study entry and at disease progression. Primary endpoint was 6-month progression-free survival. Two-stage Simon design required 85 patients to be included (EudraCT 2017-004519-38). Results Between February 2019 and November 2020, 49 patients were screened (16 RAS mutations in LB detected) and 31 included (18 assigned to arm A and 13 to arm B). The study was prematurely closed due to inadequate recruitment. Serious adverse events were more frequent in arm A (44% vs. 23%). Overall response rate was 33% (arm A) vs. 7.7% (arm B). Six-month progression-free survival rate was 66.7% (arm A) and 38.5% (arm B). Median progression-free survival was 11.0 months (arm A) and 4.0 months (arm B) (hazard ratio, 0.58). At disease progression, RAS or BRAF mutations in LB were found in 4/11 patients (36%) in arm A and 2/10 (20%) in arm B. Conclusions The BEYOND study suggests a meaningful benefit of P-FOLFIRI beyond progression to P-FOLFOX in metastatic colorectal cancer patients with WT RAS status selected by LB. This strategy deserves further investigation." @default.
• W4283711296 created "2022-06-30" @default.
• W4283711296 creator A5016120354 @default.
• W4283711296 creator A5020465946 @default.
• W4283711296 creator A5023415126 @default.
• W4283711296 creator A5028687949 @default.
• W4283711296 creator A5033580835 @default.
• W4283711296 creator A5038406441 @default.
• W4283711296 creator A5048085062 @default.
• W4283711296 creator A5049733736 @default.
• W4283711296 creator A5058939561 @default.
• W4283711296 creator A5059107350 @default.
• W4283711296 creator A5059201728 @default.
• W4283711296 creator A5060170484 @default.
• W4283711296 creator A5060205533 @default.
• W4283711296 creator A5068708772 @default.
• W4283711296 creator A5070871701 @default.
• W4283711296 creator A5079972474 @default.
• W4283711296 date "2022-06-27" @default.
• W4283711296 modified "2023-09-27" @default.
• W4283711296 title "Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01)" @default.
• W4283711296 cites W1914351667 @default.
• W4283711296 cites W1918640585 @default.
• W4283711296 cites W1992292837 @default.
• W4283711296 cites W2027371008 @default.
• W4283711296 cites W2098354753 @default.
• W4283711296 cites W2106789440 @default.
• W4283711296 cites W2112727687 @default.
• W4283711296 cites W2115735904 @default.
• W4283711296 cites W2116731538 @default.
• W4283711296 cites W2121847974 @default.
• W4283711296 cites W2123965006 @default.
• W4283711296 cites W2133399075 @default.
• W4283711296 cites W2156834559 @default.
• W4283711296 cites W2160373161 @default.
• W4283711296 cites W2331318007 @default.
• W4283711296 cites W2336525426 @default.
• W4283711296 cites W2389239223 @default.
• W4283711296 cites W2535069604 @default.
• W4283711296 cites W2553710623 @default.
• W4283711296 cites W2574977410 @default.
• W4283711296 cites W2602324018 @default.
• W4283711296 cites W2606050648 @default.
• W4283711296 cites W2607200433 @default.
• W4283711296 cites W2752652559 @default.
• W4283711296 cites W2756716076 @default.
• W4283711296 cites W2758866707 @default.
• W4283711296 cites W2800494346 @default.
• W4283711296 cites W2808460191 @default.
• W4283711296 cites W2889264838 @default.
• W4283711296 cites W2901178367 @default.
• W4283711296 cites W2936160482 @default.
• W4283711296 cites W2960942904 @default.
• W4283711296 cites W3169573209 @default.
• W4283711296 cites W3183441630 @default.
• W4283711296 doi "https://doi.org/10.1007/s12094-022-02868-x" @default.
• W4283711296 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35761123" @default.
• W4283711296 hasPublicationYear "2022" @default.
• W4283711296 type Work @default.
• W4283711296 citedByCount "4" @default.
• W4283711296 countsByYear W42837112962022 @default.
• W4283711296 countsByYear W42837112962023 @default.
• W4283711296 crossrefType "journal-article" @default.
• W4283711296 hasAuthorship W4283711296A5016120354 @default.
• W4283711296 hasAuthorship W4283711296A5020465946 @default.
• W4283711296 hasAuthorship W4283711296A5023415126 @default.
• W4283711296 hasAuthorship W4283711296A5028687949 @default.
• W4283711296 hasAuthorship W4283711296A5033580835 @default.
• W4283711296 hasAuthorship W4283711296A5038406441 @default.
• W4283711296 hasAuthorship W4283711296A5048085062 @default.
• W4283711296 hasAuthorship W4283711296A5049733736 @default.
• W4283711296 hasAuthorship W4283711296A5058939561 @default.
• W4283711296 hasAuthorship W4283711296A5059107350 @default.
• W4283711296 hasAuthorship W4283711296A5059201728 @default.
• W4283711296 hasAuthorship W4283711296A5060170484 @default.
• W4283711296 hasAuthorship W4283711296A5060205533 @default.
• W4283711296 hasAuthorship W4283711296A5068708772 @default.
• W4283711296 hasAuthorship W4283711296A5070871701 @default.
• W4283711296 hasAuthorship W4283711296A5079972474 @default.
• W4283711296 hasBestOaLocation W42837112961 @default.
• W4283711296 hasConcept C121608353 @default.
• W4283711296 hasConcept C126322002 @default.
• W4283711296 hasConcept C143998085 @default.
• W4283711296 hasConcept C168563851 @default.
• W4283711296 hasConcept C203092338 @default.
• W4283711296 hasConcept C207103383 @default.
• W4283711296 hasConcept C2776694085 @default.
• W4283711296 hasConcept C2776705615 @default.
• W4283711296 hasConcept C2778260052 @default.
• W4283711296 hasConcept C2778332735 @default.
• W4283711296 hasConcept C2780739268 @default.
• W4283711296 hasConcept C2780962732 @default.
• W4283711296 hasConcept C2781187634 @default.
• W4283711296 hasConcept C44249647 @default.
• W4283711296 hasConcept C526805850 @default.
• W4283711296 hasConcept C71924100 @default.
• W4283711296 hasConcept C90924648 @default.
• W4283711296 hasConceptScore W4283711296C121608353 @default.

• next